High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care

Stjärne, Pär; Odebäck, Peter; Ställberg, Björn; Lundberg, Johan; Olsson, Petter

doi:10.4104/pcrj.2012.00011

Cited by 31 publications

(36 citation statements)

References 21 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subjects in this study by Stjärne and colleagues reported poor QoL. 6 They noted high rates of pain/discomfort and limitation to usual activities, so understandably they desired symptom relief. But antibiotics are not always beneficial and can cause harm.…”

mentioning

confidence: 71%

“…Allergy is a risk factor for acute rhinosinusitis 7 and a quarter of the subjects in this paper 6 report having seasonal allergies. This highlights the importance of assessing for the role of allergies.…”

mentioning

confidence: 78%

“…10 Another major concern is the global overuse of antibiotics for the treatment of acute rhinosinusitis, a mainly viral disease. 11 This was largely borne out in this study by Stjärne and colleagues, 6 since 60% were treated by their provider with antibiotics. Usually, the number of patients taking a medicine is less than those that were prescribed it.…”

mentioning

confidence: 84%

“…5 Primary care providers have the major responsibility for managing this condition, and thus it is appropriate to study acute rhinosinusitis in a primary care setting. In this issue of the Primary Care Respiratory Journal, Stjärne and colleagues 6 report on the high costs and health-related QoL in acute rhinosinusitis in a Swedish primary care setting. Using a prospective, observational study design at 11 sites, QoL and cost analyses in adults with acute rhinosinusitis were assessed.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Acute rhinosinusitis — does quality of life explain continued rates of antibiotic overusage?

Friedlander

2012

Primary Care Respiratory Journal

View full text Add to dashboard Cite

mentioning

confidence: 71%

mentioning

confidence: 78%

mentioning

confidence: 84%

mentioning

confidence: 99%

See 2 more Smart Citations

Acute rhinosinusitis — does quality of life explain continued rates of antibiotic overusage?

Friedlander

2012

Primary Care Respiratory Journal

View full text Add to dashboard Cite

“…8 Data on disease severity, resource use, and HRQoL were collected at the first physician visit and at follow-up 15 (±2) days later. Baseline patient characteristics were similar to those reported for subjects in the clinical study (baseline mean MSS 8.34 and 8.39 and mean age 35 and 45 years in the clinical study and the observational study, respectively).…”

Section: Input Datamentioning

confidence: 99%

Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis

Svensson

Lundberg

Olsson

et al. 2012

Primary Care Respiratory Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Vaccines for the common cold

Montesinos-Guevara

Buitrago-Garcia

Felix

et al. 2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually < 37.8 ºC). Whilst the common cold is generally not harmful, it is a cause of economic burden due to school and work absenteeism. In the United States, economic loss due to the common cold is estimated at more than USD 40 billion per year, including an estimate of 70 million workdays missed by employees, 189 million school days missed by children, and 126 million workdays missed by parents caring for children with a cold. Additionally, data from Europe show that the total cost per episode may be up to EUR 1102. There is also a large expenditure due to inappropriate antimicrobial prescription. Vaccine development for the common cold has been difficult due to antigenic variability of the common cold viruses; even bacteria can act as infective agents. Uncertainty remains regarding the efficacy and safety of interventions for preventing the common cold in healthy people, thus we performed an update of this Cochrane Review, which was first published in 2011 and updated in 2013 and 2017. Objectives To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (April 2022), MEDLINE (1948 to April 2022), Embase (1974 to April 2022), CINAHL (1981 to April 2022), and LILACS (1982 to April 2022). We also searched three trials registers for ongoing studies, and four websites for additional trials (April 2022). We did not impose any language or date restrictions. Selection criteria Randomised controlled trials (RCTs) of any virus vaccine compared with placebo to prevent the common cold in healthy people. Data collection and analysis We used Cochrane’s Screen4Me workflow to assess the initial search results. Four review authors independently performed title and abstract screening to identify potentially relevant studies. We retrieved the full‐text articles for those studies deemed potentially relevant, and the review authors independently screened the full‐text reports for inclusion in the review, recording reasons for exclusion of the excluded studies. Any disagreements were resolved by discussion or by consulting a third review author when needed. Two review authors independently collected data on a data extraction form, resolving any disagreements by consensus or by involving a third review author. We double‐checked data transferred into Review Manager 5 software. Three review authors independently assessed risk of bias using RoB 1 tool as outlined in the Cochrane Handbook for Systematic Reviews of Interventions. We carried out statistical analysis using Review Manager 5. We did not conduct a meta‐analysis, and w...

show abstract

High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care

Abstract: Background: Few studies have investigated the impact of acute rhinosinusitis on disease-specific quality of life, and disease costs have not been studied previously in Scandinavia.

Cited by 31 publications

References 21 publications

Acute rhinosinusitis — does quality of life explain continued rates of antibiotic overusage?

Acute rhinosinusitis — does quality of life explain continued rates of antibiotic overusage?

Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis

Vaccines for the common cold

Contact Info

Product

Resources

About